Home » Stocks » ELGXQ

Endologix, Inc. (ELGXQ)

Oct 2, 2020 - ELGXQ was delisted
Stock Price: $0.0199 USD 0.0000 (0.00%)
Updated Oct 2, 2020 4:00 PM EDT

ELGXQ Stock Price Chart

Key Info

Market Cap 411,076
Revenue (ttm) 124.88M
Net Income (ttm) -59.80M
Shares Out 20.72M
EPS (ttm) -2.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 2, 2020
Last Price $0.0199
Previous Close $0.0199
Change ($) 0.0000
Change (%) 0.00%
Day's Open -
Day's Range 0.0100 - 0.0289
Day's Volume 0
52-Week Range 0.0100 - 0.1340

ELGXQ Stock News

Business Wire - 1 month ago

IRVINE, Calif.--(BUSINESS WIRE)-- #AAA--Endologix has launched the ALTO™ Abdominal Stent Graft System in Europe for the treatment of patients with abdominal aortic aneurysm (AAA)

Business Wire - 3 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Furthering its mission to transform the treatment of aortic disorders, Endologix, Inc.

Zacks Investment Research - 3 months ago

Endologix (ELGXQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Transforming the treatment of aortic disorders, Endologix® Inc.

Business Wire - 4 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Endologix announces first commercial implant of ALTO Abdominal Stent Graft System & official start of U.S.

Benzinga - 4 months ago

Shares of Endologix, Inc. (NASDAQ: ELGX), a manufacturer of medical devices for the treatment of aortic disorder, are moving to the downside Monday.

Market Watch - 4 months ago

Shares of Endologix Inc. ELGX, -2.77% plunged 41% toward a record low in premarket trading Monday, after the medical device maker filed for bankruptcy over the weekend, and announced a deal to...

Seeking Alpha - 6 months ago

Endologix, Inc. (ELGX) CEO John Onopchenko on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Endologix (ELGX) delivered earnings and revenue surprises of -19.40% and 0.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

Investors need to pay close attention to Endologix (ELGX) stock based on the movements in the options market lately.

Seeking Alpha - 9 months ago

Endologix, Inc. (ELGX) CEO John Onopchenko on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Endologix (ELGX) delivered earnings and revenue surprises of 40.00% and -0.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

Endologix (ELGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Endologix, Inc. (ELGX) CEO John Onopchenko on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Endologix (ELGX) delivered earnings and revenue surprises of 15.63% and 1.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Endologix (ELGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Endologix's (ELGX) CEO John Onopchenko on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Endologix (ELGX) delivered earnings and revenue surprises of 53.75% and 0.41%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Endologix, Inc. (ELGX).

Seeking Alpha - 1 year ago

Endologix's (ELGX) CEO John Onopchenko on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Endologix (ELGX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

About ELGXQ

Endologix develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EV... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Jun 20, 1996
CEO
John Onopchenko
Employees
488
Stock Exchange
US OTC
Ticker Symbol
ELGXQ
Full Company Profile

Financial Performance

In 2019, Endologix's revenue was $143.37 million, a decrease of -8.37% compared to the previous year's $156.47 million. Losses were -$64.76 million, -18.76% less than in 2018.

Financial Statements